Oculis (OCS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
Oculis Holding AG (OCS)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
OCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCS alerts
High impacting Oculis Holding AG news events
Weekly update
A roundup of the hottest topics
OCS
News
- Oculis Publishes Invitation to the Annual General MeetingGlobeNewswire
- Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema [Yahoo! Finance]Yahoo! Finance
- Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular EdemaGlobeNewswire
- Oculis to Participate in Upcoming Investor ConferencesGlobeNewswire
- Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis [Yahoo! Finance]Yahoo! Finance
OCS
Earnings
- 11/10/25 - Beat
OCS
Sec Filings
- 4/21/26 - Form 6-K
- 3/27/26 - Form SCHEDULE
- 3/9/26 - Form 144
- OCS's page on the SEC website